



Universiteit
Leiden
The Netherlands

Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development

Paardekooper, L.M.; Fillié-Grijpma, Y.E.; Sluijs-gelling, A.J. van der; Zlei, M.; Doorn, R. van; Vermeer, M.H.; ... ; T2B Consortium

Citation

Paardekooper, L. M., Fillié-Grijpma, Y. E., Sluijs-gelling, A. J. van der, Zlei, M., Doorn, R. van, Vermeer, M. H., ... Huijbers, M. G. (2023). Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development. *Clinical Immunology*, 257. doi:10.1016/j.clim.2023.109817

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3713848>

Note: To cite this publication please use the final published version (if applicable).



Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development

Laurent M. Paardekooper^a, Yvonne E. Fillié-Grijpma^a, Alita J. van der Sluijs-Gelling^b, Mihaela Zlei^b, Remco van Doorn^c, Maarten H. Vermeer^c, Manuela Paunovic^d, Maarten J. Titulaer^d, Silvère M. van der Maarel^a, Jacques J.M. van Dongen^{b,f}, Jan J. Verschuuren^e, Maartje G. Huijbers^{a,e,*}, On behalf of the T2B consortium

^a Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

^b Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

^c Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands

^d Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands

^e Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands

^f Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain

ARTICLE INFO

Keywords:

IgG4
Myasthenia gravis
Pemphigus
Autoimmune encephalitis
Plasma cells

ABSTRACT

A subset of autoimmune diseases is characterized by predominant pathogenic IgG4 autoantibodies (IgG4-AID). Why IgG4 predominates in these disorders is unknown. We hypothesized that dysregulated B cell maturation or aberrant class switching causes overrepresentation of IgG4⁺ B cells and plasma cells. Therefore, we compared the B cell compartment of patients from four different IgG4-AID with two IgG1-3-AID and healthy donors, using flow cytometry. Relative subset abundance at all maturation stages was normal, except for a, possibly treatment-related, reduction in immature and naïve CD5⁺ cells. IgG4⁺ B cell and plasma cell numbers were normal in IgG4-AID patients, however they had a (sub)class-independent 8-fold increase in circulating CD20⁺CD138⁺ cells. No autoreactivity was found in this subset. These results argue against aberrant B cell development and rather suggest the autoantibody subclass predominance to be antigen-driven. The similarities between IgG4-AID suggest that, despite displaying variable clinical phenotypes, they share a similar underlying immune profile.

1. Introduction

An important factor that determines the pathophysiological mechanism in antibody-mediated autoimmune diseases is the dominant autoantibody (sub)class. The majority of antibody-mediated autoimmune diseases are caused by pro-inflammatory autoantibody subclasses such as ImmunoglobulinG 1 (IgG1) and IgG3 [1]. These antibody subclasses, through activation of complement or immune cell-mediated cytotoxicity, damage the target organ causing the disease-associated symptoms [2]. In addition, their bivalent nature allows them to cross-link their target antigens, often causing internalization and loss of surface antigen function which further contributes to the pathology [3,4]. In contrast, IgG4 is generally considered an anti-inflammatory antibody subclass. IgG4 has low affinity for most Fc receptors and complement factor C1q [5–8]. This means that IgG4 usually does not induce

antibody-mediated phagocytosis, antibody-dependent cell-mediated cytotoxicity or complement-mediated tissue damage. Additionally, IgG4 antibodies are uniquely capable of Fab-arm exchange meaning exchange of antibody half molecules (one heavy chain and one light chain) resulting in bispecific, functionally monovalent IgG4 molecules [9–12]. Furthermore, IgG4 has a relatively high affinity for its antigen [13–15] which is likely caused by its late order in switch region position, its relatively later occurrence in an immune response and consequently more time to acquire VH mutations [16,17]. Because of the inability to activate the immune system and its relatively high affinity, the effects of IgG4 are usually caused by blocking the function of the target antigen [5,18–20]. Interestingly, a group of autoimmune diseases (AID) predominated by autoantibodies of the IgG4 subclass exists [18].

To date, 29 different AID fit the criteria for IgG4-AID [21]. These IgG4-AID affect different organ systems and are generally rare with a

* Corresponding author at: Eindhovenweg 20, 2333ZC Leiden, The Netherlands.

E-mail address: m.g.m.huijbers@lumc.nl (M.G. Huijbers).

<https://doi.org/10.1016/j.clim.2023.109817>

Received 6 July 2023; Accepted 25 October 2023

Available online 2 November 2023

1521-6616/© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

prevalence of 0.001-5/10.000 individuals [22]. During the last decades *in vitro* and *in vivo* studies have directly confirmed the pathogenicity of IgG4 autoantibodies in at least six IgG4-AID, and more are expected to follow [23–26]. Insight in the pathophysiology and immunological characteristics of these autoimmune diseases highlights several commonalities between these disorders: 1) IgG4 autoantibodies block essential protein-protein interactions thereby causing disease, 2) on a group level, IgG4 serum titers are only marginally increased [27–29], 3) they respond favorably to rituximab treatment [30–33] and 4) they show a strong association with HLA-class II haplotypes HLA-DQB1*05 and HLA-DRB1*04 [21,34]. These observations suggest that, although IgG4-AID affect different organs and cause a variety of symptoms, they may in fact share a similar underlying immunological profile.

Why IgG4 predominates in these autoimmune responses is poorly understood. This is relevant however as the switching to IgG4 may make autoantibodies more pathogenic [35] and treatment strategy may be adjusted accordingly. Class switching to IgG4 is known to occur in response to prolonged exposure to certain antigens such as bee venom and peanuts [5,36] or under influence of Th2 cytokines IL-4, IL-10 and IL-13 [37–40]. Indeed, these cytokines were found increased in IgG4-AID patients and cross-reactivity was observed with autoantibodies from pemphigus patients with IgG4-inducing allergens [41–43]. Lastly, dysregulated B cell maturation or aberrant class switching may cause overrepresentation of IgG4⁺ B cells and IgG4 plasma cells in immune responses. To further understand what is causing the IgG4 predominance in IgG4-AID, we investigated in detail the many IgH-isotype subsets of the circulating B cell compartment in four archetypical IgG4-AID and compared them to two IgG1-3-AID and age-matched healthy controls.

2. Methods

2.1. Study population

AID patients with Muscle-specific kinase (MuSK) myasthenia gravis (MG), acetylcholine receptor (AChR) MG, Lambert-Eaton myasthenic syndrome (LEMS) or pemphigus (vulgaris, foliaceus and paraneoplastica) were recruited from the Leiden University Medical Centre

(2017–2021). We obtained blood samples for 10 patients per disease except for MuSK MG, for which we obtained 11 samples. Two Contactin-associated protein-like 2 (CASPR2) encephalitis and three leucine-rich glioma inactivated (LGI1) encephalitis patients were recruited from the Erasmus University Medical Center (2019–2021). Patients were included based on the presence of symptoms matching MG, pemphigus, encephalitis or LE [44–46] and a positive titer on a serological test for the respective autoantibody upon standard clinical testing. Patients were excluded if they had received rituximab treatment within the past 12 months. This cutoff is based on literature, although B cell reconstitution post-rituximab may vary between patients [47–53]. Blood samples were also obtained from 10 age- and sex-matched healthy controls. These healthy controls were recruited by the LUMC Voluntary Donor Service (LuVDS). Fig. 1 and Supplemental Table 1 provide a detailed overview of the study population.

2.2. Isolation of peripheral blood mononuclear cells

Peripheral blood mononuclear cells (PBMCs) were isolated from 60 to 90 ml of sodium-Heparin anticoagulated peripheral blood samples by Ficoll-amidotrizoate density gradient centrifugation. Following isolation, cells were immediately frozen at -80 °C at a density of 5-10•10⁶ per ml in Recovery Cell Freezing medium (Thermo Fisher Scientific, Waltham, MA, USA) in a Mr. Frosty Freezing Container (Thermo Fisher Scientific, Waltham, MA, USA) for 24 h before transfer to liquid nitrogen storage.

2.3. Flow cytometry

The B cell subsets and B cell receptor (sub)classes were identified in freshly thawed PBMCs using the standardized EuroFlow 12-color IgH-isotype B-cell tube [54–56], with the exception of CD62L which was replaced by a Zombie Yellow cell viability stain (BioLegend, San Diego, CA, USA) (see Sup. Table 2 for a detailed overview). At least 10•10⁶ cells were stained for 30 min in the dark in 100 µl (75 µl EuroFlow B cell tube mix and 25 µl Cytognos isotype mix) staining solution according to the EuroFlow SOP for sample preparation and staining of markers followed by immediate analysis (www.EuroFlow.org).




Fig. 1. Pre-germinal center B cell fractions of IgG4-AID and IgG1-3-AID patients. (A) Immature, (B) naive CD5⁺ and (C) naive B cell counts as percentage of all pre-germinal center (GC) B cells. Treatment status is marked per patient. When treatment consisted of multiple therapies in the past, the most recent one is visualized. For all panels, IgG4-AID were compared to both healthy controls and IgG1-3-AID by one-way ANOVA followed by unpaired Student's *t*-test (* *p* < 0.05; ** *p* < 0.01; *** *p* < 0.005).

Flow cytometry was performed on a BD FACS LSR Fortessa 4L (BD Biosciences, San Jose, CA, USA) at the Flow cytometry Core Facility (FCF) of Leiden University Medical Center (LUMC) in Leiden, Netherlands (<https://www.lumc.nl/research/facilities/fcf>). At least 3×10^6 cells were acquired per sample. Instrument setup was according to the EuroFlow standardized operating procedures [57]. See Sup. Fig. 1 for a detailed overview of the gating strategy.

Plasma cells were sorted on a BD FACSAria 3 cell sorter (BD Biosciences, San Jose, CA, USA). The gating strategy is detailed in Sup. Fig. 2. In brief, freshly thawed PBMCs were stained for expression of CD38, CD20, CD138 and CD19. Viable cells were identified using Zombie Green cell viability stain (BioLegend, San Diego, CA, USA). See Sup. Table 3 for a detailed overview of the staining. A dump channel for T cells, NK cells and macrophages was created by staining PBMCs for expression of CD3, CD14 and CD56.

2.4. Plasma cell culture

After bulk sorting, plasma cell subtypes were cultured in RPMI1640 (Thermo Fisher Scientific, Waltham, MA, USA) supplemented 10% heat-inactivated fetal bovine serum, IL-6 (10 ng/ml; Thermo Fisher Scientific, Waltham, MA, USA), IL-21 (50 ng/ml; Thermo Fisher Scientific, Waltham, MA, USA), IFN- α (100 U/ml; Merck, Rahway, NJ, USA), BAFF (20 ng/ml; Miltenyi Biotec, Bergisch Gladbach, NRW, Germany), chemically defined lipid mixture 1 (1/200; Thermo Fisher Scientific, Waltham, MA, USA), MEM amino acid solution (1 \times ; Sigma-Aldrich, St. Louis, MO, USA) on γ -irradiated M2-10B4 stromal cells (1.5×10^4 /well, 100 μ l/well) in 96-well plates [58]. Every 7 days, 50 μ l culture supernatant was aspirated for IgG detection (anti-MuSK and total IgG) and replaced with fresh medium.

2.5. ELISA

Plasma cell culture medium samples were screened for antibody production using a total human IgG ELISA assay and for MuSK reactivity using a previously described MuSK ELISA assay [59].

2.6. Statistics

Flow cytometry data was blinded and then analyzed using Infinicyt 2.0 (Cytognos, Salamanca, Spain). Statistical analyses were performed using Prism 9 (GraphPad Software, San Diego, CA, USA). Data was log transformed and significance was assessed by one-way ANOVA followed by unpaired Student's *t*-test unless otherwise specified. IgG4-AID patients were compared to healthy controls and to IgG1-3-AID patients. *p*-values below 0.05 are considered statistically significant (* *p* < 0.05; ** *p* < 0.01; *** *p* < 0.005).

2.7. Study approval

This study was approved by the local medical ethics committee of the Leiden University Medical Centre (CME protocolnumber P17.011). All subjects provided written informed consent prior to participation and experiments were in accordance with the Declaration of Helsinki, including current revisions, and Good Clinical Practice guidelines.

3. Results

3.1. Study population

To investigate the role of aberrant B cell development or class switching in subclass predominated AID, the B cell compartments of four IgG4-AID were immunophenotyped and compared to two IgG1-3-AID and healthy donors. An overview of the demographics of the study population is given in Table 1. Median age at time of blood draw (*p* = 0.96, one-way ANOVA) and male:female ratio (*p* = 0.31, Pearson's χ^2

test at $D_f = 6$) were comparable between groups. The CASPR2 encephalitis patient samples did not contain enough cells to perform a reliable in-depth phenotyping analysis (Sup. Fig. 3), therefore they were only included in the pre-germinal center analyses. One pemphigus patient sample was excluded due to an abnormally low total B cell count which can be attributed to the patient receiving rituximab infusion just before blood draw. In this study we aimed to include as many treatment naïve patients as possible or those only receiving low doses of immunosuppression to limit a treatment bias. Several patients however received multiple treatments simultaneously. A complete description of the included study population is given in Sup. Table 1.

3.2. Decreased numbers of immature and naïve B cells in patients with AID may be treatment related

To investigate early B cell development stages we investigated the pre-germinal center (GC) B cells across all cohorts. The relative abundance of immature (Fig. 1A) and naïve CD5⁺ (Fig. 1B) B cells was lower in MuSK MG and pemphigus patients compared to healthy controls and LEMS patients. Consequently, the relative abundance of naïve CD5⁻ B cells was increased in these patients (Fig. 1C). LGI1 and CASPR2 encephalitis patients show a similar trend, but due to the low number of patients per group this analysis lacked power. Treatment status may influence immature B cell numbers [61]. The observed reduction in cell numbers does not seem to be explained by the use of a single drug. Notably, the variance within the autoimmune disease groups was considerably larger than in healthy donors.

3.3. B memory cell numbers are largely normal in IgG1-3-AID and IgG4-AID

GC formation is essential for the development of a functional antibody repertoire and is initiated by B cell receptor signaling after antigen encounter [62,63]. Pre-GC B cells are mostly of the IgM or IgD isotype and have not undergone affinity maturation yet as both class switching and somatic hypermutation take place in the GC [63–65]. In the context of autoimmunity, post-GC antigen-experienced mature memory B cells

Table 1
Study population.

	Number of patients (excluded)	Age (median, min/max)	Sex (M: F)	Immunosuppressive treatment (number of patients)
MuSK	11 (0)	59 (27–79)	4:7	Untreated (2), prednisone (4), rituximab (3), azathioprine (4), IVIG (1), cellcept (2), plasmapheresis (1), unknown (2)
Myasthenia Gravis				
Pemphigus	10 (1)	58 (26–75)	5:4	Prednisone (8), clobetasol lotion (1) rituximab (2; 1 excluded)
LGI1 encephalitis	2 (0)	– (48–62)	1:1	Untreated (1), prednisone (1), IVIG (1)
CASPR2 encephalitis	3 (included in pre-GC only)	65 (57–69)	3:0	Untreated (1), azathioprine (2)
Lambert-Eaton Myasthenic Syndrome	10 (0)	56 (49–74)	3:7	None (7), prednisone (1), azathioprine (1), IVIG (1), hydrocortisone (1)
AChR Myasthenia Gravis	10 (0)	63 (18–79)	7:3	None (5), prednisone (5), IVIG (1)
Healthy control	10 (0)	58 (44–68)	5:5	–
<i>p</i> -value (column statistic)	–	0.96 (1-way ANOVA)	0.31 (χ^2)	–

and plasma cells are particularly of interest as they may harbor the autoreactive cell subsets. Overall total memory B cell levels are normal in all autoimmunity groups (Fig. 2A). The total number of switched (IgM⁺/D⁺CD27⁺) (Fig. 2B), double-negative (IgM⁺/D⁻CD27⁻) (Fig. 2C) and atypical (IgM⁺/D⁻CD21⁻CD27⁻) (Fig. 2D) memory B cells are similar to healthy donors. After stratification for B cell receptor (sub)class, total memory B cell (Fig. 2E), switched (Fig. 2F) and double-negative (Fig. 2G) memory B cell fractions are still similar between groups. Only in MuSK MG patients did we observe significantly lower atypical IgG4 B cells (IgM⁺/D⁻CD21⁻CD27⁻) compared to healthy controls and IgG1-3 AID patients (Fig. 2H). Surprisingly, atypical IgG4 memory B cells were increased in the IgG1-3 AID LEMS and AChR MG compared to IgG4-AID patients. Definitions of atypical B cells vary, as they are still relatively understudied and highly heterogeneous [66,67]. Furthermore, their phenotype seems to be influenced by disease status [68]. Because the EuroFlow panel lacks deep specific markers for atypical B cells, such as CD11c, we defined them as class-switched, CD19⁺CD20⁺CD21⁻CD27⁻ cells in accordance with Ambegaonkar et al. and Gao et al. [66,69].

3.4. IgG4-AID patients have 8-fold increased circulating mature plasma cell numbers

Differentiating B cells can also commit to the plasma cell lineage upon leaving the GC [70]. These plasmablasts express CD27 and CD38 and during maturation into plasma cells they gradually lose expression of CD20 and gain expression of CD138 [71–74]. Total plasma cell fractions were comparable in all groups (Fig. 3A). When stratified by B cell receptor (sub)class, we observe increases in IgG1⁺ and IgG3⁺ plasma cells, as well as a decrease in IgA1⁺ plasma cells only seen in the pemphigus patients (Fig. 3B). Only IgG3⁺ plasma cells are increased in MuSK MG patients. There were no changes in IgG4⁺ plasma cell fractions for any of the IgG4-AID [72,73]. To investigate plasma cell maturation in IgG4-AID, we quantified three specific plasma cell maturation stages: CD20⁺CD138⁻, CD20⁻CD138⁻ and CD20⁻CD138⁺. IgG1-3-AID patients show a slight reduction in CD20⁻CD138⁻ intermediate plasma cells (Fig. 4A). When stratified by B cell receptor (sub)class this reduction is observed in IgG1⁺ and IgG2⁺ plasma cells (Fig. 4B-C). At the same time, IgG1⁺ and IgG2⁺ CD20⁺CD138⁻ plasmablasts are increased in IgG1-3-AID patients. Interestingly, in all three IgG4-AID patient groups we observe increased fractions of the CD20⁻CD138⁺ fully matured plasma cells in comparison to both healthy controls and IgG1-3-AID (on average 8-fold increase, range 4-14; Fig. 4A). This increase is not specific to IgG4⁺ plasma cells and instead is observed in IgG1⁺ (pemphigus only), IgG2⁺, IgA1⁺ and IgA2⁺ (pemphigus only) CD20⁻CD138⁺ plasma cells (Fig. 4D, F, G, respectively).

Mature plasma cells of IgG4-AID patients seem to segregate in two populations. Immunosuppressive treatment may alter B cell compartment composition. The acute nature of these autoimmune disease often requires patients to start immunomodulatory treatment quickly after diagnosis. The samples included in this study were prioritized on no or low amounts of immunosuppressive treatment. However, some patients did receive prednisone, rituximab or azathioprine (Sup. Table 1). To investigate if these treatments biased our analysis we plotted the data including the treatment (Sup. Figs. 4 and 5). The low numbers in each treatment category prevent statistical analysis, but this plot may suggest that untreated patients have higher fractions of mature plasma cells and that treatment may have lowered their numbers.

To investigate whether plasma cell numbers and the increase in mature plasma cells in IgG4-AID may be related to disease severity in these patient, we performed simple linear regression analysis on the pemphigus and MuSK MG cohorts (Sup. Fig. 7). There was no evidence that these plasma cell numbers correlated with the disease severity status or autoantibody titer.

3.5. Autoreactivity is not enriched in any of the circulating plasma cell maturation stages

To investigate whether these CD20⁻CD138⁺ plasma cells of IgG4-AID patients include autoantibody-producing cells, we sorted CD20⁺CD138⁻, CD20⁻CD138⁻ and CD20⁻CD138⁺ plasma cells of MuSK MG patients and compared them to healthy controls (Fig. 5A). We selected 3 untreated MuSK MG patients with relatively high numbers of mature plasma cells (marked in Fig. 5B and Sup. Table 1) for this experiment. After sorting, these populations were taken into culture to collect supernatants for screening on MuSK-specific antibodies [23]. Despite detecting total IgG in supernatants of all three plasma cell subsets (Fig. 5C), no MuSK-specific IgG was found in any of the subsets except for 1 patient in the CD20⁺CD138⁻ population (Fig. 5D).

4. Discussion

To investigate whether predominance of IgG4 autoantibodies in IgG4-AID is caused by aberrations in B cell development or class switching, we compared the full peripheral blood B cell compartment of the IgG4-AID MuSK MG, pemphigus, LGI1 and CASPR2 encephalitis with the IgG1-3-AID AChR MG and LEMS, as well as healthy controls. Generally, B cell relative frequencies, and therefore also B cell development, were normal across all autoimmune diseases tested. B cell numbers from our healthy donors matched well with previous reports [54]. IgG4⁺ memory B cell or IgG4⁺ plasma cell fractions were not increased in IgG4-AID patients. This suggests that IgG4-AID patients do not have aberrant B cell receptor class switching favoring an IgG4 response. This is in line with studies showing that IgG4 serum levels are only mildly, if at all, increased in IgG4-AID patients [27–29]. Generalized IgG4⁺ B cell fractions in IgG4-AID patients being comparable to healthy controls suggests that the IgG4 predominance in autoimmune responses is selective, antigen-specific and perhaps antigen-driven (see below). The HLA class II associations as well as the favorable response to rituximab across IgG4-AID, in combination with the data presented here, further support the hypothesis of an overarching immunophenotype across IgG4-AID. This data strengthens the idea that IgG4-AID represent a different disease entity from IgG4-related diseases (IgG4-RDs). IgG4-RD are hallmarked by increased numbers of circulating IgG4⁺ memory B cells and IgG4⁺ plasmablasts coupled to high IgG4 serum titers and tissue fibrosis [75]. While various autoantibodies have been found in IgG4-RD patients, these are mainly of the IgG1 subclass and are not known to correlate consistently with the disease [76–78]. Serum IgG4 autoantibody titers do correlate with disease severity in IgG4-AID and cause disease upon passive transfer [25,26,79]. Despite the central role of IgG4 in both disease groups, IgG4-AID and IgG4-RDs should not be considered part of the same disease spectrum.

IgG4-AID patients were found to have an overall increase in mature (CD20⁻CD138⁺) plasma cells, but this increase was not unique to IgG4⁺ cells. Increased mature plasma cells were previously reported in some [80], but not all [81] studies on AChR MG patients. We did not observe this in AChR MG patients included in this study. Plasma cell numbers decrease with age [54,82]. The differences between the above-mentioned AChR MG studies may be explained by this confounding effect. We did not observe any age-dependent plasma cell decrease in our study population (Sup. Fig. 6). Disease activity may also reflect in plasma cell subset frequencies, however we did not observe a correlation with several disease activity markers QMG [83] and MG-ADL [84] scores for MuSK MG disease severity, autoantibody titer and clinician-reported disease severity for pemphigus (Sup. Fig. 7). Increased CD138⁺ plasma cells are a hallmark of several chronic AID [85,86] and both MuSK MG and pemphigus likely fit the same classification. Why the other AID did not show increased mature plasma cell numbers is not known.

CD138⁺ plasma cells are usually contained within the bone marrow and are considered responsible for long term immunity [87]. This fully




Fig. 2. Memory B cell fractions of IgG4-AID and IgG1-3-AID patients. (A) Overall memory B cell (CD19⁺CD20⁺CD27⁺) counts normalized to total B cell counts, (B) switched memory B cell (IgM⁺/D⁺CD19⁺CD20⁺CD27⁺) counts normalized to total B cell counts, (C) double-negative B cell (IgM⁺/D⁺CD19⁺CD20⁺CD27⁻) counts normalized to total B cell counts, (F) atypical B cell (IgM⁺/D⁺CD19⁺CD20⁺CD21⁻CD27⁻) counts normalized to total B cell counts. (E), (F), (G), (H): Respectively total memory, switched, double-negative and atypical B cell counts normalized to total memory B cell counts and stratified by B cell receptor (sub)class. For all panels, IgG4-AID were compared to both healthy controls and IgG1-3-AID by one-way ANOVA followed by unpaired Student's *t*-test (* *p* < 0.05; ** *p* < 0.01; *** *p* < 0.005).




Fig. 3. Plasma cell fractions of IgG4-AID and IgG1-3-AID patients. (A) Overall plasma cell (CD19⁺CD20⁺/CD138⁺) counts normalized to total B cell counts. (B) Plasma cell counts normalized to total plasma cell counts stratified per B cell receptor IgH (sub)class. For all panels, IgG4-AID were compared to both healthy controls and IgG1-3-AID by one-way ANOVA followed by unpaired Student's *t*-test (* *p* < 0.05; ** *p* < 0.01; *** *p* < 0.005).

matured plasma cell subset shows the highest levels of antibody secretion. Why certain immune responses induce such mature responses is not fully understood, but has been reported at day 7 post-vaccination for common vaccines against pathogens such as mumps, tetanus, pertussis and measles [71,87–89]. In IgG4-AID these mature plasma cell levels may be increased as a result of: 1) a net increase in their numbers due to a change in antigen-independent maturation, 2) stronger migratory signals that may stimulate these cells to leave the bone marrow and become increased in PBMCs, possibly during migration towards sites with high target antigen availability, or, 3) these may contain the autoantibody producing plasma cell subsets which increase their overall numbers due to chronic activation. Although there was no selective increase of IgG4 subclass mature plasma cells, we tested the third hypothesis by sorting the early, intermediate and mature plasma cell populations of MuSK MG patients and testing for autoantibody production. We did not find evidence for autoreactivity in any of these subsets. Although we detected robust total IgG production in these cultures, we cannot exclude a technical limitation as sorting and subsequently culturing these delicate plasma cell populations is challenging [90]. A role for these mature plasma cells in the autoimmune response may be considered unlikely due to the fact that they do not express CD20, but rituximab (anti-CD20 therapy) treatment is usually effective in IgG4-AID [30–33]. IgG4 responses are mostly mediated by short-lived plasma cells which do not migrate to the bone marrow [91]. Bone marrow holds many of the cell types that contribute to humoral immunity. PBMCs may therefore not accurately reflect aberrations present in the bone marrow compartment. Whether peripheral or bone marrow mature plasma cells play a role in the pathophysiology of IgG4-AID requires further investigation.

Pre-germinal center subsets of immature and naïve CD5⁺ B cells were decreased in IgG4-AID. Previous work has shown that immunosuppressants, especially azathioprine, selectively lower naïve CD5⁺ B cell counts, which may explain this observation [61]. Indeed, azathioprine treated patients show the most severe decrease in naïve CD5⁺ B cell numbers in our cohorts (Fig. 1). Other immunomodulatory treatments may also significantly bias immunophenotyping analysis. The severity of the IgG4-AID requiring rapid treatment combined with a poor response to symptomatic treatments made inclusion of untreated patients challenging [92,93]. We therefore aimed to include as much immunosuppressive treatment naïve patients for this study, but, due to the rarity of

these samples, were compelled to also include some who received (low amounts of) immunosuppression. Although the included patients all experienced significant disease symptoms, we cannot fully exclude that in some patients the treatment regimens affected the B cell compartment. Future immune profiling studies should aim to only include untreated individuals whenever possible.

In the memory B cell compartment, we found no differences between any of the patient groups in both total cell abundance or when stratified for the switched (IgM⁺/D⁻CD27⁺) or double negative (IgM⁻/D⁻CD27⁻) subsets. We did observe a significant decrease of IgG4⁺ atypical (IgM⁻/D⁻CD21⁻CD27⁻) memory B cells in MuSK MG patients when compared to healthy controls or IgG1-AID patients. Like IgG4 responses in general, atypical B cell counts increase with prolonged and repeated antigen exposure [94] and are associated with several autoimmune diseases [68,95–98]. However, we did not detect this in our study for the other AID. Notably, the EuroFlow panel used in our study lacks the markers for deep, specific identification of atypical B cell subsets, such as CD11c or FCRL5 [67,68]. Instead, we defined atypical B cells as class-switched, CD19⁺CD20⁺CD21⁻CD27⁻ cells. Given the involvement of atypical B cells in autoimmunity, our findings may warrant further research into the involvement of atypical B cells in IgG4-AID.

The question thus remains why these autoimmune diseases are characterized by predominant IgG4 autoantibody responses. One possibility is that the antigen itself directs the response towards IgG4. Certain antigens are known to drive IgG4 responses, such as bee venom and certain biologicals [99]. Specifically for pemphigus there is evidence of desmoglein 1/3 autoantibody development following exposure to walnut or sand fly antigens [41–43]. There is no evidence yet for comparable molecular mimicry events in other IgG4-AID. However, given the strong correlation between these antigens and IgG4, molecular mimicry could be a plausible factor in the etiology of other IgG4-AID.

5. Conclusion

Aberrant B cell development or class switching is not likely to underly the predominance of IgG4 autoimmune responses in IgG4-AID. There are increased levels of mature CD20-CD138+ plasma cells in these patients, however this phenomenon was not (sub)class specific and we could not link this to production of autoreactive antibodies in MuSK MG. Taken together, these observations suggests that the IgG4 response in




Fig. 4. Distribution of plasma cell maturation stages of IgG4-AID and IgG1-3-AID patients. (A) Overall plasma cell (CD19⁺CD20⁺/CD138^{+/−}) counts normalized to total B cell counts and subdivided for maturation status normalized to total plasma cell counts. The same plasma cell populations are shown for IgG1 (B), IgG2 (C), IgG3 (D), IgG4 (E), IgA1 (F) and IgA2 (G). For all panels, IgG4-AID were compared to both healthy controls and IgG1-3-AID by one-way ANOVA followed by unpaired Student's *t*-test (* *p* < 0.05; ** *p* < 0.01; *** *p* < 0.005).




Fig. 5. Plasma cell subset sorting and follow-up culture to investigate autoreactivity. (A) Representative flow plots and gating strategy of plasma cell sorting into CD20⁺CD138⁻, CD20⁻CD138⁻ and CD20⁻CD138⁺ subsets. (B) Excerpt from Fig. 4A, patients selected for plasma cell sort are shown as filled dots. (C) Total IgG titers produced by plasma cell subsets after culturing for 14 days. (D) MuSK-reactive IgG titers produced by plasma cell subsets after culturing for 14 days. The dashed lines represent the average anti-MuSK IgG titer of the control sample with a range of 3 standard deviations.

IgG4-AID patients has a different etiology.

CRediT authorship contribution statement

Laurent M. Paardekooper: Formal analysis, Writing – original draft, Visualization, Data curation. **Yvonne E. Fillié-Grijpma:** Investigation, Formal analysis, Data curation. **Alita J. van der Sluijs-Gelling:** Investigation, Formal analysis. **Mihaela Zlei:** Methodology, Resources. **Remco van Doorn:** Resources. **Maarten H. Vermeer:** Resources. **Manuela Paunovic:** Resources. **Maarten J. Titulaer:** Resources. **Silvère M. van der Maarel:** Writing – review & editing. **Jacques J.M. van Dongen:** Conceptualization, Writing – review & editing, Resources, Methodology. **Jan J. Verschuuren:** Conceptualization, Writing – review & editing, Resources. **Maartje G. Huijbers:** Conceptualization, Writing – review & editing, Funding acquisition, Supervision, Project administration.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.clim.2023.109817>.

Declaration of Competing Interest

JV, SM, MH are coinventors on MuSK-related patents. LUMC and JV, SM and MH receive royalties from these patents. SM is a Board member for Renogenyx. LUMC receives royalties on a MuSK ELISA. JV is consultant for Argenx, Alexion, NMD Pharma. MH receives financial support from the LUMC (OIO 2017, Gisela Thier Fellowship 2021), Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (LSHM19130), Prinses Beatrix Spierfonds (W.OR-19.13). MJT is member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases–Project ID No 739543 (ERN-RITA; HCP Erasmus MC). MJT has filed a patent, on behalf of the Erasmus MC, for methods for typing neurological disorders and cancer, and devices for use therein, and has received research funds for serving on a scientific advisory board of Horizon Therapeutics, for consultation at Guidepoint Global LLC, for consultation at UCB, for teaching colleagues at Novartis. MJT has received an unrestricted research grant from Euroimmun AG, and from CSL Behring. JJMvD reports to be the chairman of the EuroFlow Consortium. JJMvD is also listed as inventor on the patent “Means and methods for multiparameter cytometry-based leukocyte subsetting” (PCT/NL2020/050688, filing date 5 November 2019), owned by the EuroFlow scientific consortium; JJMvD reports an Educational Services Agreement from BD Biosciences (San José, CA) and a Scientific Advisor Agreement with Cytognos/BD Biosciences; all

related fees and honoraria are for the involved university departments at Leiden University Medical Center and University of Salamanca. The remaining authors declare no interests. The LUMC is part of the European Reference Network for Rare Neuromuscular Diseases [ERN EURO-NMD] and the Netherlands Neuromuscular Center.

The other authors have declared that no conflict of interest exists.

Data availability

All raw flow cytometry data for this work is directly accessible via the Flow Repository under experiment ID FR-FCM-Z6K2 [60]. Derived data supporting the findings of this study are available from the corresponding author on request.

Acknowledgements

The authors gratefully acknowledge dr. Jelle Goeman for his advice on statistical procedures.

The authors gratefully acknowledge the Flow cytometry Core Facility (FCF) of Leiden University Medical Center (LUMC) in Leiden, the Netherlands (<https://www.lumc.nl/research/facilities/fcf>), coordinated by dr. K. Schepers and M. Hametman, run by the FCF Operators E.F.E de Haas, J.P. Jansen, D.M. Lowie, S. van de Pas, and G.I.J. Reyneveld (Directors: Prof. F.J.T. Staal and Prof. J.J.M. van Dongen) for technical support.

The authors gratefully acknowledge the LUMC Vrijwillige Donoren Service (LuVDS) for providing healthy donor material.

The collaboration project is financed by the PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under project code LSHM18055-SGF to stimulate public-private partnerships and co-financing by health foundations that are part of the SGF.

The authors acknowledge the support of patient partners, private partners and active colleagues of the T2B consortium; see website: www.target-to-b.nl.

References

- [1] M. Volkov, M. Coppola, R. Huizinga, F. Eftimov, T.W.J. Huizinga, A.J. van der Kooij, L.E.M. Oosten, J. Raaphorst, T. Rispens, R. Sciarrillo, M.J. Titulaer, L. Wieske, R.E.M. Toes, M.G.M. Huijbers, K.A. van Schie, D. van der Woude, Comprehensive overview of autoantibody isotype and subclass distribution, *J. Allergy Clin. Immunol.* 150 (2022) 999–1010, <https://doi.org/10.1016/j.jaci.2022.05.023>.

- [2] G. Vidarsson, G. Dekkers, T. Rispen, IgG subclasses and allotypes: from structure to effector functions, *Front. Immunol.* 5 (2014), <https://doi.org/10.3389/fimmu.2014.00520>.
- [3] E.G. Hughes, X. Peng, A.J. Gleichman, M. Lai, L. Zhou, R. Tsou, T.D. Parsons, D. R. Lynch, J. Dalmau, R.J. Balice-Gordon, Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis, *J. Neurosci.* 30 (2010) 5866–5875, <https://doi.org/10.1523/JNEUROSCI.0167-10.2010>.
- [4] R.J. Ludwig, K. Vanhoorelbeke, F. Leyboldt, Z. Kaya, K. Bieber, S.M. McLachlan, L. Komorowski, J. Luo, O. Cabral-Marques, C.M. Hammers, J.M. Lindstrom, P. Lamprecht, A. Fischer, G. Riemekasten, C. Tersteeg, P. Sondermann, B. Rapoport, K.P. Wandinger, C. Probst, A. el Beidaq, E. Schmidt, A. Verkman, R. A. Manz, F. Nimmerjahn, Mechanisms of autoantibody-induced pathology, *Front. Immunol.* 8 (2017) 603, <https://doi.org/10.3389/FIMMU.2017.00603/BIBTEX>.
- [5] L.C. Lighaam, T. Rispen, The Immunobiology of immunoglobulin G4, *Semin. Liver Dis.* 36 (2016) 200–215, <https://doi.org/10.1055/s-0036-1584322>.
- [6] P. Bruhns, B. Iannascoli, P. England, D.A. Mancardi, N. Fernandez, S. Jorieux, M. Daéron, Specificity and affinity of human Fcγ4a receptors and their polymorphic variants for human IgG subclasses, *Blood.* 113 (2009) 3716–3725, <https://doi.org/10.1182/BLOOD-2008-09-179754>.
- [7] J.S. van der Zee, P. van Swieten, R.C. Aalberse, Inhibition of complement activation by IgG4 antibodies, *Clin. Exp. Immunol.* 64 (1986) 415. [/pmc/articles/PMC1542347/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/abstract/PMC1542347/?report=abstract) (accessed July 13, 2022).
- [8] C.I. Bindon, G. Hale, M. Bruggemann, H. Waldmann, Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q, *J. Exp. Med.* 168 (1988) 127, <https://doi.org/10.1084/JEM.168.1.127>.
- [9] M.G. Huijbers, D.L. Vergoossen, Y.E. Fillié-Grijpma, I.E. van Es, M.T. Konig, L. M. Slot, H. Veelken, J.J. Plomp, S.M. van der Maarel, J.J. Verschuuren, MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity, *Neurol. (R)* *Neuroimmunol. Neuroinflammation* 6 (2019), e547, <https://doi.org/10.1212/NXI.0000000000000547>.
- [10] A.F. Labrijn, T. Rispen, J. Meesters, R.J. Rose, T.H. den Bleker, S. Loverix, E.T. J. van den Bremer, J. Neijssen, T. Vink, I. Lasters, R.C. Aalberse, A.J.R. Heck, J.G. J. van de Winkel, J. Schuurman, P.W.H.I. Parren, Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3–CH3 interaction strength, *J. Immunol.* 187 (2011) 3238–3246, <https://doi.org/10.4049/jimmunol.1003336>.
- [11] T. Rispen, A.M. Davies, P. Ooijevaar-de Heer, S. Absalah, O. Bende, B.J. Sutton, G. Vidarsson, R.C. Aalberse, Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange, *J. Biol. Chem.* 289 (2014) 6098–6109, <https://doi.org/10.1074/jbc.M113.541813>.
- [12] M.V.D.N. Kolschoten, J. Schuurman, M. Losen, W.K. Bleeker, P. Martínez-Martínez, E. Vermeulen, T.H. Den Bleker, L. Wiegman, T. Vink, L.A. Aarden, M. H. de Baets, J.G.J. Van De Winkel, R.C. Aalberse, P.W.H.I. Parren, Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange, *Science.* 317 (2007) 1554–1557, <https://doi.org/10.1126/SCIENCE.1144603>.
- [13] M.E. Devey, K.M. Bleasdale-Barr, P. Bird, P.L. Amlot, Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin, *Immunology* 70 (1990) 168. [/pmc/articles/PMC1384188/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/abstract/PMC1384188/?report=abstract) (accessed September 5, 2023).
- [14] M.E. Devey, S.R. Lee, D. Richards, D.M. Kemeny, Serial studies on the functional affinity and heterogeneity of antibodies of different IgG subclasses to phospholipase A2 produced in response to bee-venom immunotherapy, *J. Allergy Clin. Immunol.* 84 (1989) 326–330, [https://doi.org/10.1016/0091-6749\(89\)90416-8](https://doi.org/10.1016/0091-6749(89)90416-8).
- [15] C.J. Hofbauer, S.F.J. Whelan, M. Hirschler, P. Allacher, F.M. Horling, J.P. Lawo, J. Oldenburg, A. Tiede, C. Male, J. Windyga, A. Greinacher, P.N. Knöbl, G. Schrenk, J. Koehn, F. Scheiflinger, B.M. Reipert, Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans, *Blood.* 125 (2015) 1180–1188, <https://doi.org/10.1182/BLOOD-2014-09-598268>.
- [16] K.J.L. Jackson, Y. Wang, A.M. Collins, Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels, *Immunol. Cell Biol.* 92 (2014) 729–733, <https://doi.org/10.1038/ICB.2014.44>.
- [17] K. Kitaura, H. Yamashita, H. Ayabe, T. Shini, T. Matsutani, R. Suzuki, Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis, *Front. Immunol.* 8 (2017), 244326, <https://doi.org/10.3389/FIMMU.2017.00389/BIBTEX>.
- [18] M.G. Huijbers, L.A. Querol, E.H. Niks, J.J. Plomp, S.M. van der Maarel, F. Graus, J. Dalmau, I. Illa, J.J. Verschuuren, The expanding field of IgG4-mediated neurological autoimmune disorders, *Eur. J. Neurol.* 22 (2015) 1151–1161, <https://doi.org/10.1111/ene.12758>.
- [19] Y. Futei, M. Amagai, K. Ishii, K. Kuroda-Kinoshita, K. Ohya, T. Nishikawa, Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus, *J. Dermatol. Sci.* 26 (2001) 55–61, [https://doi.org/10.1016/s0923-1811\(00\)00158-4](https://doi.org/10.1016/s0923-1811(00)00158-4).
- [20] M. Amagai, Adhesion molecules. I: keratinocyte-keratinocyte interactions; Cadherins and pemphigus, *J. Invest. Dermatol.* 104 (1995) 146–152, <https://doi.org/10.1111/1523-1747.EP12613668>.
- [21] I. Konecny, V. Yilmaz, K. Lazaridis, J. Tzartos, T.L. Lenz, S. Tzartos, E. Tüzün, F. Leyboldt, Common denominators in the immunobiology of IgG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic Purpura and autoimmune encephalitis have in common? *Front. Immunol.* 0 (2021) 3609, <https://doi.org/10.3389/FIMMU.2020.605214>.
- [22] I. Konecny, Update on IgG4-mediated autoimmune diseases: new insights and new family members, *Autoimmun. Rev.* 19 (2020), <https://doi.org/10.1016/j.autrev.2020.102646>.
- [23] M.G. Huijbers, W. Zhang, R. Klooster, E.H. Niks, M.B. Friese, K.R. Straasheijm, P. E. Thijssen, H. Vrolijk, J.J. Plomp, P. Vogels, M. Losen, S.M. van der Maarel, S. J. Burden, J.J. Verschuuren, MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 20783–20788, <https://doi.org/10.1073/pnas.1313944110>.
- [24] B. Rock, C.R. Martins, A.N. Theofilopoulos, R.S. Balderas, G.J. Anhalt, R.S. Labib, S. Futamura, E.A. Rivitti, L.A. Diaz, The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem), *N. Engl. J. Med.* 320 (1989) 1463–1469, <https://doi.org/10.1056/NEJM198906013202206>.
- [25] R. Klooster, J.J. Plomp, M.G. Huijbers, E.H. Niks, K.R. Straasheijm, F.J. Detmers, P. W. Hermans, K. Sleijpen, A. Verrips, M. Losen, P. Martínez-Martínez, M.H. de Baets, S.M. van der Maarel, J.J. Verschuuren, Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice, *Brain.* 135 (2012) 1081–1101, <https://doi.org/10.1093/BRAIN/AWS025>.
- [26] I. Konecny, A new classification system for IgG4 autoantibodies, *Front. Immunol.* 9 (2018), <https://doi.org/10.3389/fimmu.2018.00097>.
- [27] D.L.E. Vergoossen, A.M. Ruiten, K.R. Keene, E.H. Niks, M.R. Tannemaat, E. Stribos, A.F. Lipka, E.C.J. van der Zijde, M.J.D. van Tol, J.A. Bakker, B.A. Wevers, E. Westerberg, L.S. Borges, O.C. Tong, D.P. Richman, I. Illa, A.R. Punga, A. Evoli, S. M. van der Maarel, J.J. Verschuuren, M.G. Huijbers, Enrichment of serum IgG4 in MuSK myasthenia gravis patients, *J. Neuroimmunol.* 373 (2022), <https://doi.org/10.1016/j.jneuroim.2022.577978>.
- [28] T. Funakoshi, L. Lunardon, C.T. Ellebrecht, A.R. Nagler, C.E. O'Leary, A.S. Payne, Enrichment of total serum IgG4 in patients with pemphigus, *Br. J. Dermatol.* 167 (2012) 1245–1253, <https://doi.org/10.1111/j.1365-2133.2012.11144.x>.
- [29] V. Endmayer, C. Tunc, L. Ergin, A. de Rosa, R. Weng, L. Wagner, T.-Y.Y. Yu, A. Fichtenbaum, T. Perkmann, H. Haslacher, N. Kozakowski, C. Schwaiger, G. Ricken, S. Hametner, S. Klotz, L.A. Dutra, C. Lechner, D. de Simoni, K.-N. N. Poppert, G.J. Müller, S. Pirker, W. Pirker, A. Angelovski, M. Valach, M. Maestri, M. Guida, R. Ricciardi, F. Frommlet, D. Sieghart, M. Pinter, K. Kircher, G. Artacker, R. Höftberger, I. Konecny, L. Almeida Dutra, C. Lechner, D. Siré de Simoni, K.-N. N. Poppert, G. Johannes Müller, S. Pirker, W. Pirker, A. Angelovski, M. Valach, M. Maestri, M. Guida, R. Ricciardi, F. Frommlet, D. Sieghart, M. Pinter, K. Kircher, G. Artacker, R. Höftberger, I. Konecny, F. Alberici, J. Delgado Alves, G. Saruhan Direskeneli, D.A. Rosa, de D. Simoni, Y. T-y, de D. Simoni, P. K-n, Anti-neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: a comparative study, *Front. Immunol.* 12 (2022) 1. www.frontiersin.org (accessed March 28, 2022).
- [30] J. Díaz-Manera, E. Martínez-Hernández, L. Querol, R. Klooster, R. Rojas-García, X. Suárez-Calvet, J.L. Muñoz-Blanco, C. Mazia, K.R. Straasheijm, E. Gallardo, C. Juárez, J.J. Verschuuren, I. Illa, Long-lasting treatment effect of rituximab in MuSK myasthenia, *Neurology.* 78 (2012) 189–193, <https://doi.org/10.1212/WNL.0b013e3182407982>.
- [31] P. Joly, M. Maho-Vaillant, C. Prost-Squarcioni, V. Hebert, E. Houivet, S. Calbo, F. Caillot, M.L. Golinski, B. Labelle, C. Picard-Dahan, C. Paul, M.A. Richard, J. D. Bouaziz, S. Duvert-Lehembre, P. Bernard, F. Caux, M. Alexandre, S. Ingen-Housz-Oro, P. Vabres, E. Delaporte, G. Queux, A. Dupuy, S. Debarbieux, M. Avenel-Audran, M. D'Incan, C. Bedane, N. Bénétou, D. Julien, N. Dupin, L. Misery, L. Machet, M. Beylot-Barry, O. Dereure, B. Sasselous, T. Vermeulen, J. Benichou, P. Musette, First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial, *Lancet.* 389 (2017) 2031–2040, [https://doi.org/10.1016/S0140-6736\(17\)30070-3](https://doi.org/10.1016/S0140-6736(17)30070-3).
- [32] A. Ronaghy, R.D. Streilein, R.P. Hall, Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP), *J. Dermatol. Sci.* 74 (2014) 93–94, <https://doi.org/10.1016/j.jdermsci.2013.11.014>.
- [33] A. Khosroshahi, D.B. Bloch, V. Deshpande, J.H. Stone, Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease, *Arthritis Rheum.* 62 (2010) 1755–1762, <https://doi.org/10.1002/ART.27435>.
- [34] A. Panhuber, G. Lamorte, V. Bruno, H. Cetin, W. Bauer, R. Höftberger, A.C. Erber, F. Frommlet, I. Konecny, A systematic review and meta-analysis of HLA class II associations in patients with IgG4 autoimmunity, *Sci. Rep.* 12 (2022) 9229, <https://doi.org/10.1038/s41598-022-13042-2>.
- [35] D.L.E. Vergoossen, J.J. Plomp, C. Gstöttner, Y.E. Fillié-Grijpma, R. Augustinus, R. Verpalen, M. Wührer, P.W.H.I. Parren, E. Dominguez-Vega, S.M. van der Maarel, J.J. Verschuuren, M.G. Huijbers, Functional monoavalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis, *Proc. Natl. Acad. Sci. U. S. A.* 118 (2021), <https://doi.org/10.1073/PNAS.2020635118/-/DCSUPPLEMENTAL>.
- [36] T. Boonpiyathad, N. Meyer, M. Moniuszko, M. Sokolowska, A. Eljaszewicz, O. F. Wirz, M.M. Tomasiak-Lozowska, A. Bodzenta-Lukaszyk, K. Ruxrungtham, W. van de Veer, High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers, *Allergy.* 72 (2017) 407–415, <https://doi.org/10.1111/ALL.12966>.
- [37] P. Jeannin, S. Lecoanet, Y. Delneste, J.F. Gauchat, J.Y. Bonnefoy, IgE versus IgG4 production can be differentially regulated by IL-10, *J. Immunol.* 160 (1998) 3555–3561, <http://www.ncbi.nlm.nih.gov/pubmed/9531318> (accessed February 12, 2020).
- [38] J.S. Satoguina, E. Weyand, J. Larbi, A. Hoerauf, T regulatory-1 cells induce IgG4 production by B cells: role of IL-10, *J. Immunol.* 174 (2005) 4718–4726, <https://doi.org/10.4049/jimmunol.174.8.4718>.
- [39] M. Akiyama, H. Yasuoka, K. Yoshimoto, T. Takeuchi, Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease, *Cytokine.* 110 (2018) 416–419, <https://doi.org/10.1016/j.cyto.2018.05.009>.

- [40] M. Takeuchi, K. Ohno, K. Takata, Y. Gion, T. Tachibana, Y. Orita, T. Yoshino, Y. Sato, Interleukin 13-positive mast cells are increased in immunoglobulin G4-related sialadenitis, *Sci. Rep.* 5 (2015), <https://doi.org/10.1038/SREP07696>.
- [41] L. Lin, T.P. Moran, B. Peng, J. Yang, D.A. Culton, H. Che, S. Jiang, Z. Liu, S. Geng, Y. Zhang, L.A. Diaz, Y. Qian, Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a “hit-and-run” mechanism, *J. Allergy Clin. Immunol.* 144 (2019) 720–728.e4, <https://doi.org/10.1016/j.jaci.2019.04.020>.
- [42] N. Li, V. Aoki, Z. Liu, P. Prisanh, J.G. Valenzuela, L.A. Diaz, From insect bites to a skin autoimmune disease: a conceivable pathway to endemic pemphigus foliaceus, *Front. Immunol.* 13 (2022), <https://doi.org/10.3389/FIMMU.2022.907424>.
- [43] Y. Qian, J.S. Jeong, M. Maldonado, J.G. Valenzuela, R. Gomes, C. Teixeira, F. Evangelista, B. Qaqish, V. Aoki, G. Hans, E.A. Rivitti, D. Eaton, L.A. Diaz, Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen, *J. Immunol.* 189 (2012) 1535–1539, <https://doi.org/10.4049/JIMMUNOL.1200842>.
- [44] F. Graus, M.J. Titulaer, R. Balu, S. Benseler, C.G. Bien, T. Cellucci, I. Cortese, R. C. Dale, J.M. Gelfand, M. Geschwind, C.A. Glaser, J. Honnorat, R. Höftberger, T. Iizuka, S.R. Irani, E. Lancaster, F. Leypoldt, H. Prüss, A. Rae-Grant, M. Reindl, M. R. Rosenfeld, K. Rostásy, A. Saiz, A. Venkatesan, A. Vincent, K.-P. Wandinger, P. Waters, J. Dalmau, A clinical approach to diagnosis of autoimmune encephalitis, *Lancet Neurol.* 15 (2016) 391–404, [https://doi.org/10.1016/S1474-4422\(15\)00401-9](https://doi.org/10.1016/S1474-4422(15)00401-9).
- [45] V. Melchionda, K.E. Harman, Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management, *Clin. Exp. Dermatol.* 44 (2019) 740–746, <https://doi.org/10.1111/ced.14041>.
- [46] R.M. Pascuzzi, C.L. Bodkin, Myasthenia gravis and Lambert-Eaton myasthenic syndrome: new developments in diagnosis and treatment, *Neuropsychiatr. Dis. Treat.* 18 (2022) 3001–3022, <https://doi.org/10.2147/NDT.S296714>.
- [47] M.J. Leandro, G. Cambridge, M.R. Ehrenstein, J.C.W. Edwards, Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis, *Arthritis Rheum.* 54 (2006) 613–620, <https://doi.org/10.1002/ART.21617>.
- [48] J.H. Anolik, J.W. Friedberg, B. Zheng, J. Barnard, T. Owen, E. Cushing, J. Kelly, E. C.B. Milner, R.I. Fisher, I. Sanz, B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny, *Clin. Immunol.* 122 (2007) 139–145, <https://doi.org/10.1016/J.CLIM.2006.08.009>.
- [49] P.D. Patel, A. Rubinstein, B cell reconstitution following rituximab in autoimmune disorders, *J. Allergy Clin. Immunol.* 129 (2012) AB215, <https://doi.org/10.1016/j.jaci.2011.12.086>.
- [50] J. Worch, O. Makarova, B. Burkhardt, Immunoreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? *Cancers (Basel)* 7 (2015) 305, <https://doi.org/10.3390/CANCERS7010305>.
- [51] M. Colucci, R. Carsetti, S. Cascioli, F. Casiraghi, A. Perna, L. Ravà, B. Ruggiero, F. Emma, M. Vivarelli, B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome, *J. Am. Soc. Nephrol.* 27 (2016) 1811–1822, <https://doi.org/10.1681/ASN.2015050523/-DCSUPPLEMENTAL>.
- [52] C. Mitchell, C.B. Crayne, R.Q. Cron, Patterns of B cell repletion following rituximab therapy in a pediatric rheumatology cohort, *ACR Open Rheumatol.* 1 (2019) 527, <https://doi.org/10.1002/ACR2.11074>.
- [53] R. Jiang, M.L. Fichtner, K.B. Hoehn, M.C. Pham, P. Stathopoulos, R.J. Nowak, S. H. Kleinstein, K.C. O'Connor, K.C. O'Connor, K.C. O'Connor, Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses, *JCI Insight.* 5 (2020), <https://doi.org/10.1172/jci.insight.136471>.
- [54] E. Blanco, M. Pérez-Andrés, S. Arriba-Méndez, T. Contreras-Sanfeliciano, I. Criado, O. Pelak, A. Serra-Caetano, A. Romero, N. Puig, A. Remesal, J. Torres Canizales, E. López-Granados, T. Kalina, A.E. Sousa, M. van Zelm, M. van der Burg, J.J.M. van Dongen, A. Orfao, Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood, *J. Allergy Clin. Immunol.* 141 (2018) 2208–2219.e16, <https://doi.org/10.1016/j.jaci.2018.02.017>.
- [55] E. Blanco, M. Pérez-Andrés, S. Arriba-Méndez, C. Serrano, I. Criado, L. del Pino-Molina, S. Silva, I. Madruga, M. Bakardjieva, C. Martins, A. Serra-Caetano, A. Romero, T. Contreras-Sanfeliciano, C. Bonroy, F. Sala, A. Martín, J.M. Bastida, F. Lorente, C. Prieto, I. Dávila, M. Marcos, T. Kalina, M. Vlkova, Z. Chovancova, A. I. Cordeiro, J. Philippé, F. Haerynck, E. López-Granados, A.E. Sousa, M. van der Burg, J.J.M. van Dongen, A. Orfao, Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with COVID and immunoglobulin subclass deficiencies, *J. Allergy Clin. Immunol.* 144 (2019) 809–824, <https://doi.org/10.1016/J.JACI.2019.02.017>.
- [56] J.J.M. van Dongen, M. van der Burg, T. Kalina, M. Perez-Andres, E. Mejstrikova, M. Vlkova, E. Lopez-Granados, M. Wentink, A.-K. Kienzler, J. Philippé, A.E. Sousa, M.C. van Zelm, E. Blanco, A. Orfao, EuroFlow-based Flowcytometric diagnostic screening and classification of primary immunodeficiencies of the lymphoid system, *Front. Immunol.* 10 (2019) 1271, <https://doi.org/10.3389/fimmu.2019.01271>.
- [57] T. Kalina, J. Flores-Montero, V.H.J. van der Velden, M. Martin-Ayuso, S. Böttcher, M. Ritgen, J. Almeida, L. Lhermitte, V. Asnafi, A. Mendonça, R. de Tute, M. Cullen, L. Sedek, M.B. Vidriales, J.J. Pérez, J.G. te Marvelde, E. Mejstrikova, O. Hrusak, T. Szczepaski, J.J.M. van Dongen, A. Orfao, EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols, *Leukemia.* 26 (2012) 1986–2010, <https://doi.org/10.1038/LEU.2012.122>.
- [58] M. Cocco, S. Stephenson, M.A. Care, D. Newton, N.A. Barnes, A. Davison, A. Rawstron, D.R. Westhead, G.M. Doody, R.M. Toozie, In vitro generation of long-lived human plasma cells, *J. Immunol.* 189 (2012) 5773–5785, <https://doi.org/10.4049/jimmunol.1103720>.
- [59] M.G. Huijbers, A.F.D. Vink, E.H. Niks, R.H. Westhuis, E.W. van Zwet, R.H. de Meel, R. Rojas-García, J. Díaz-Manera, J.B. Kuks, R. Klooster, K. Straasheijm, A. Evoli, I. Illa, S.M. van der Maarel, J.J. Verschuuren, Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity, *J. Neuroimmunol.* 291 (2016) 82–88, <https://doi.org/10.1016/J.JNEUROIM.2015.12.016>.
- [60] J. Spidlen, K. Breuer, C. Rosenberg, N. Kotecha, R.R. Brinkman, FlowRepository: a resource of annotated flow cytometry datasets associated with peer-reviewed publications, *Cytometry A* 81A (2012) 727–731, <https://doi.org/10.1002/CYTO.A.22106>.
- [61] E. Strijbos, M.M. van Ostaijen-ten Dam, C. Vervat, M.W. Schilham, M.G. M. Huijbers, M.J.D. van Tol, J.J.G.M. Verschuuren, The effect of immunosuppression or thymectomy on the response to tetanus revaccination in myasthenia gravis, *J. Neuroimmunol.* (2022), 577930, <https://doi.org/10.1016/j.jneuroim.2022.577930>.
- [62] J.G. Cyster, C.D.C. Allen, B Cell Responses: Cell Interaction Dynamics and Decisions. <https://pubmed.ncbi.nlm.nih.gov/31002794/>, 2019. (Accessed 10 May 2021).
- [63] H.W. King, N. Orban, J.C. Riches, A.J. Clear, G. Warnes, S.A. Teichmann, L. K. James, Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics, *Sci. Immunol.* 6 (2021), <https://doi.org/10.1126/sciimmunol.abe6291>.
- [64] J. Stavnezer, C.E. Schrader, IgH chain class switch recombination: mechanism and regulation, *J. Immunol.* 193 (2014) 5370–5378, <https://doi.org/10.4049/jimmunol.1401849>.
- [65] L. Mesin, J. Ersching, G.D. Victora, Germinal center B cell dynamics, *Immunity.* 45 (2016) 471–482, <https://doi.org/10.1016/J.IMMUNI.2016.09.001>.
- [66] X. Gao, I.A. Cockburn, The development and function of CD11c+ atypical B cells - insights from single cell analysis, *Front. Immunol.* 13 (2022), <https://doi.org/10.3389/FIMMU.2022.979060>.
- [67] H. Li, F. Borrego, S. Nagata, M. Tolnay, Fc receptor-like 5 expression distinguishes two distinct subsets of human circulating tissue-like memory B cells, *J. Immunol.* 196 (2016) 4064–4074, <https://doi.org/10.4049/JIMMUNOL.1501027>.
- [68] S. Wang, J. Wang, V. Kumar, J.L. Karnell, B. Naiman, P.S. Gross, S. Rahman, K. Zerrouki, R. Hanna, C. Morehouse, N. Holowecyj, H. Liu, K. Casey, M. Smith, M. Parker, N. White, J. Riggs, B. Ward, G. Bhat, B. Rajan, R. Grady, C. Groves, Z. Manna, R. Goldbach-Mansky, S. Hasni, R. Siegel, M. Sanjuan, K. Streicher, M. P. Cancro, R. Kolbeck, R. Ettinger, IL-21 drives expansion and plasma cell differentiation of autoreactive CD11cHiTbet+ B cells in SLE, *Nat. Commun.* 9 (2018), <https://doi.org/10.1038/S41467-018-03750-7>.
- [69] A.A. Ambegaonkar, P. Holla, B.L. Dizon, H. Sohn, S.K. Pierce, Atypical B cells in chronic infectious diseases and systemic autoimmunity: puzzles with many missing pieces, *Curr. Opin. Immunol.* 77 (2022), <https://doi.org/10.1016/J.COI.2022.102227>.
- [70] D. Suan, C. Sundling, R. Brink, Plasma cell and memory B cell differentiation from the germinal center, *Curr. Opin. Immunol.* 45 (2017) 97–102, <https://doi.org/10.1016/J.COI.2017.03.006>.
- [71] Y. Qian, C. Wei, F.E.H. Lee, J. Campbell, J. Halliley, J.A. Lee, J. Cai, Y.M. Kong, E. Sadat, E. Thomson, P. Dunn, A.C. Seegmiller, N.J. Karandikar, C.M. Tipton, T. Mosmann, I. Sanz, R.H. Scheuermann, Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data, *Cytometry B Clin. Cytom.* 78 (Suppl. 1) (2010), <https://doi.org/10.1002/CYTO.B.20554>.
- [72] H.E. Mei, T. Yoshida, G. Muehlinghaus, F. Hiepe, T. Dörner, A. Radbruch, B. F. Hoyer, Phenotypic analysis of B-cells and plasma cells, *Methods Mol. Med.* 136 (2007) 3–18, https://doi.org/10.1007/978-1-59745-402-5_1.
- [73] M. Jourdan, A. Caraux, G. Caron, N. Robert, G. Fiol, T. Réme, K. Bolloré, J.-P. Vendrell, S. Le Gallou, F. Mourcin, J. De Vos, A. Kassambara, C. Duperray, D. Hose, T. Fest, K. Tarte, B. Klein, Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation, *J. Immunol.* 187 (2011) 3931–3941, <https://doi.org/10.4049/JIMMUNOL.1101230>.
- [74] P. Martínez-Murillo, L. Pramanik, C. Sundling, K. Hulthenby, P. Wretenberg, M. Spångberg, G.B. Karlsson Hedestam, CD138 and CD31 double-positive cells comprise the functional antibody-secreting plasma cell compartment in primate bone marrow, *Front. Immunol.* 7 (2016) 242, <https://doi.org/10.3389/FIMMU.2016.00242/BIBTEX>.
- [75] T. Kamisawa, N. Funata, Y. Hayashi, Y. Eishi, M. Koike, K. Tsuruta, A. Okamoto, N. Egawa, H. Nakajima, A new clinicopathological entity of IgG4-related autoimmune disease, *J. Gastroenterol.* 38 (2003) 982–984, <https://doi.org/10.1007/s00535-003-1175-y>.
- [76] J.M. Löhr, R. Faissner, D. Koczan, P. Beverunge, C. Bassi, B. Brors, R. Eils, L. Frulloni, A. Funk, W. Halangk, R. Jesnowski, L. Kaderali, J. Kleeff, B. Krüger, M. M. Lerch, R. Lösel, M. Magnani, M. Neumaier, S. Nittka, M. Sahin-Tóth, J. Sanger, S. Serafini, M. Schnölzer, H.J. Thierse, S. Wandschneider, G. Zamboni, G. Klöppel, Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process, *Am. J. Gastroenterol.* 105 (2010) 2060–2071, <https://doi.org/10.1038/AJG.2010.141>.
- [77] M. Asada, A. Nishio, K. Uchida, M. Kido, S. Ueno, N. Uza, K. Kiriya, S. Inoue, H. Kitamura, S. Ohashi, H. Tamaki, T. Fukui, M. Matsuura, K. Kawasaki, T. Nishi, N. Watanabe, H. Nakase, T. Chiba, K. Okazaki, Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis, *Pancreas.* 33 (2006) 20–26, <https://doi.org/10.1097/O1.MPA.0000226881.48204.FD>.

- [78] L.M. Hubers, H. Vos, A.R. Schuurman, R. Erken, R.P. Oude Elferink, B. Burgering, S.F.J. van de Graaf, U. Beuers, Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease, *Gut*. 67 (2018) 728–735, <https://doi.org/10.1136/GUTJNL-2017-314548>.
- [79] K. Doppler, L. Appeltshausser, K. Wilhelmi, C. Villmann, S.D. Dib-Hajj, S. G. Waxman, M. Mäurer, A. Weishaupt, C. Sommer, Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies, *J. Neurol. Neurosurg. Psychiatry* 86 (2015) 720–728, <https://doi.org/10.1136/JNNP-2014-309916>.
- [80] Y. Zhang, X. Jia, Y. Xia, H. Li, F. Chen, J. Zhu, X. Zhang, Y. Zhang, Y.Z. Wang, Y. Xu, M. Pan, X. Huang, T. Yu, L. Fu, C. Xiao, D. Geng, Altered expression of transcription factors IRF4 and IRF8 in peripheral blood B cells is associated with clinical severity and circulating plasma cells frequency in patients with myasthenia gravis, *Autoimmunity*. 51 (2018) 126–134, <https://doi.org/10.1080/08916934.2018.1454913>.
- [81] Y. Hu, J. Wang, J. Rao, X. Xu, Y. Cheng, L. Yan, Y. Wu, N. Wu, X. Wu, Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis, *Int. Immunopharmacol.* 80 (2020), 106130, <https://doi.org/10.1016/j.intimp.2019.106130>.
- [82] A. Caraux, B. Klein, B. Paiva, C. Bret, A. Schmitz, G.M. Fuhler, N.A. Bos, H. E. Johnsen, A. Orfao, Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells, *Haematologica*. 95 (2010) 1016–1020, <https://doi.org/10.3324/haematol.2009.018689>.
- [83] R.J. Barohn, D. McIntire, L. Herbelin, G.I. Wolfe, S. Nations, W.W. Bryan, Reliability testing of the quantitative myasthenia gravis score, *Ann. N. Y. Acad. Sci.* 841 (1998) 769–772, <https://doi.org/10.1111/J.1749-6632.1998.TB11015.X>.
- [84] G.I. Wolfe, L. Herbelin, S.P. Nations, B. Foster, W.W. Bryan, R.J. Barohn, Myasthenia gravis activities of daily living profile, *Neurology*. 52 (1999) 1487–1489, <https://doi.org/10.1212/WNL.52.7.1487>.
- [85] T.D. Steinmetz, G.M. Verstappen, S.R. Schulz, L. de Wolff, R. Wilbrink, A. Visser, J. Terpstra, H. Bootsma, F.G.M. Kroese, Maturity of circulating antibody-secreting cells is associated with disease features in primary Sjögren's syndrome, *Arthritis Rheum.* (2022), <https://doi.org/10.1002/ART.42422>.
- [86] C.M. Tipton, C.F. Fucile, J. Darce, A. Chida, T. Ichikawa, I. Gregoretti, S. Schieferl, J. Hom, S. Jenks, R.J. Feldman, R. Mehr, C. Wei, F.E.H. Lee, W.C. Cheung, A. F. Rosenberg, I. Sanz, Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus, *Nat. Immunol.* 16 (2015) 755–765, <https://doi.org/10.1038/NL3175>.
- [87] J.L. Halliley, C.M. Tipton, J. Liesveld, A.F. Rosenberg, J. Darce, I.v. Gregoretti, L. Popova, D. Kaminiski, C.F. Fucile, I. Albizua, S. Kyu, K.Y. Chiang, K.T. Bradley, R. Burack, M. Slifka, E. Hammarlund, H. Wu, L. Zhao, E.E. Walsh, A.R. Falsey, T. D. Randall, W.C. Cheung, I. Sanz, F.E.H. Lee, Long-lived plasma cells are contained within the CD19-CD38hiCD138+ subset in human bone marrow, *Immunity* 43 (2015) 132–145, <https://doi.org/10.1016/j.immuni.2015.06.016>.
- [88] A.M. Diks, P. Versteegen, C. Teodosio, R.J. Groenland, B. de Mooij, A.M. Buisman, A. Torres-Valle, M. Pérez-Andrés, A. Orfao, G.A.M. Berbers, J.J.M. van Dongen, M. A. Berkowska, Age and primary vaccination background influence the plasma cell response to pertussis booster vaccination, *Vaccines (Basel)*. 10 (2022) 136, <https://doi.org/10.3390/VACCINES10020136/S1>.
- [89] A.M. Diks, H. de Graaf, C. Teodosio, R.J. Groenland, B. de Mooij, M. Ibrahim, A. R. Hill, R.C. Read, J.J.M. van Dongen, M.A. Berkowska, Distinct early cellular kinetics in participants protected against colonization upon *Bordetella pertussis* challenge, *J. Clin. Invest.* 133 (2023), <https://doi.org/10.1172/JCI163121>.
- [90] L. Khodadadi, Q. Cheng, A. Radbruch, F. Hiepe, The maintenance of memory plasma cells, *Front. Immunol.* 0 (2019) 721, <https://doi.org/10.3389/FIMMU.2019.00721>.
- [91] P.-P.A. Unger, L.C. Lighaam, E. Vermeulen, S. Kruithof, M. Makuch, E.L. Culver, R. van Bruggen, E.B.M.M. Remmerswaal, I.J.M. ten Berge, R.W. Emmens, H.W.M. M. Niessen, E. Barnes, G.J. Wolbink, S.M. van Ham, T. Rispens, R. van Bruggen, E. B.M.M. Remmerswaal, I.J.M. ten Berge, R.W. Emmens, H.W.M.M. Niessen, E. Barnes, G.J. Wolbink, S.M. van Ham, T. Rispens, U. PA, L. LC, V. E, K. S, M. M, C. EL, van B. R, R. EBM, T.B. IJM, E. RW, N. HWM, B. E, W. GJ, van H. SM, R. T, Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses, *Eur. J. Immunol.* 50 (2020) 1113–1125, <https://doi.org/10.1002/eji.201948454>.
- [92] A. Evoli, P.E. Alboini, V. Damato, R. Iorio, C. Provenzano, E. Bartocioni, M. Marino, Myasthenia gravis with antibodies to MuSK: an update, *Ann. N. Y. Acad. Sci.* 1412 (2018) 82–89, <https://doi.org/10.1111/nyas.13518>.
- [93] J. Dalmau, F. Graus, Antibody-mediated encephalitis, *N. Engl. J. Med.* 378 (2018) 840–851, https://doi.org/10.1056/NEJMRA1708712/SUPPL_FILE/NEJMRA1708712_DISCLOSURES.PDF.
- [94] H.J. Sutton, R. Aye, A.H. Idris, R. Vistein, E. Nduati, O. Kai, J. Mwacharo, X. Li, X. Gao, T.D. Andrews, M. Koutsakos, T.H.O. Nguyen, M. Nekrasov, P. Milburn, A. Eltahla, A.A. Berry, N. KC, S. Chakravarty, B.K.L. Sim, A.K. Wheatley, S.J. Kent, S.L. Hoffman, K.E. Lyke, P. Bejon, F. Luciani, K. Kedzierska, R.A. Seder, F. M. Ndungu, I.A. Cockburn, Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans, *Cell Rep.* 34 (2021), <https://doi.org/10.1016/j.celrep.2020.108684>.
- [95] C. Wehr, H. Eibel, M. Masilamani, H. Ilges, M. Schlesier, H.H. Peter, K. Warnatz, A new CD21low B cell population in the peripheral blood of patients with SLE, *Clin. Immunol.* 113 (2004) 161–171, <https://doi.org/10.1016/J.CLIM.2004.05.010>.
- [96] I. Isnardi, Y.-S. Ng, L. Menard, G. Meyers, D. Saadoun, I. Srdanovic, J. Samuels, J. Berman, J.H. Buckner, C. Cunningham-Rundles, E. Meffre, Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones, *Blood*. 115 (2010) 5026–5036, <https://doi.org/10.1182/blood-2009-09-243071>.
- [97] K. Thorarindottir, A. Camponeschi, I. Gertsson, I.-L. Mårtensson, CD21–/low B cells: a snapshot of a unique B cell subset in health and disease, *Scand. J. Immunol.* 82 (2015) 254–261, <https://doi.org/10.1111/SJI.12339>.
- [98] D. Saadoun, B. Terrier, J. Bannock, T. Vazquez, C. Massad, I. Kang, F. Joly, M. Rosenzweig, D. Sene, P. Benech, L. Musset, D. Klatzmann, E. Meffre, P. Cacoub, Expansion of autoreactive unresponsive CD21–/low B cells in Sjögren's syndrome-associated lymphoproliferation, *Arthritis Rheum.* 65 (2013) 1085–1096, <https://doi.org/10.1002/ART.37828>.
- [99] R.C. Aalberse, R. van der Gaag, J. van Leeuwen, Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response, *J. Immunol.* 130 (1983) 722–726. <http://www.ncbi.nlm.nih.gov/pubmed/6600252> (accessed September 14, 2022).